A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma
Andres F. Espinoza, Roma H. Patel, Kalyani R. Patel, Andrew Badachhape, Richard S. Whitlock, Rohit Srivastava, Saiabhiroop R. Govindu, Ashley T. Duong, Abhishek Kona, Pavan Kureti, Bryan W. Armbruster, Dina Kats, Ramakrishnan Rajaram Srinivasan, Lacey E. Dobrolecki, Xinjian Yu, Mohammad Javad Najaf Panah, Barry Zorman, Stephen F. Sarabia, Martin Urbicain, Angela M. Major, Karl‐Dimiter Bissig, Charles Keller, Michael T. Lewis, Andras Heczey, Pavel Sumazin, Dolores López‐Terrada, Sarah E. Woodfield, Sanjeev A. Vasudevan
Topics & Concepts
HepatoblastomaPanobinostatRefractory (planetary science)MedicineOncologyHistone deacetylaseInternal medicineCancer researchPharmacologyHistoneBiologyGeneAstrobiologyBiochemistryHepatocellular Carcinoma Treatment and PrognosisHistone Deacetylase Inhibitors ResearchManagement of metastatic bone disease